ArticleHealth science reports2026
Impact of Donor Age, Sex, and ABO Compatibility on Outcomes After Matched Unrelated Donor Hematopoietic Stem Cell Transplantation for Acute Leukemia: A Retrospective Single-Center Cohort Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Donor-related factors, including donor age, sex, and ABO compatibility, remain clinically relevant considerations in matched unrelated donor hematopoietic stem cell transplantation (MUD-HSCT). However, their independent contribution to post-transplant outcomes in contemporary practice is difficult to define, particularly in smaller institutional cohorts. We evaluated the association of selected donor characteristics with transplant outcomes in adult patients with acute leukemia undergoing MUD-HSCT. Methods: This retrospective single-center cohort study included 85 consecutive patients with acute myeloid leukemia (AML; Results: The median recipient age was 27 years (range, 14-61), and the median donor age was 30 years (range, 14-73). Based on the Disease Risk Index recorded in the institutional database, 54 patients (63.5%) had high-risk disease and 31 (36.5%) had standard-risk disease. Donor age ≥ 30 years was not significantly associated with OS, DFS, GRFS, relapse, or NRM in either AML or ALL. ABO compatibility was also not significantly associated with these outcomes. In ALL, female donor sex was associated with inferior GRFS compared with male donor sex (HR, 3.21; 95% CI, 1.44-7.16; Conclusion: In this single-center cohort of patients undergoing MUD-HSCT for acute leukemia, donor age and ABO compatibility were not statistically associated with major transplant outcomes. Female donor sex was associated with inferior GRFS in ALL, but this finding should be interpreted cautiously given the limited subgroup size, low event numbers, and absence of multivariable adjustment. Larger multicenter studies incorporating disease biology, MRD status, and transplant-related covariates are needed to validate these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.